Adma Biologics, Inc. (ADMA): who owns it and who trades it
As of Nov 16, 2026, ADMA insiders reported 14 open-market sales worth $3.8M and 5 purchases worth $468K in the last 12 months, with 55% of the sale value made under pre-set 10b5-1 plans. The largest seller was Adam S Grossman (CEO), with $3.5M. 8 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling ADMA Biologics
From the latest filingsOverall: more selling than buying. Funds and insiders mostly sold. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ADMA
321 funds and institutions reported ADMA shares worth $1.7B at the end of Q2 2026, about 90% of the company. The largest holder is BlackRock, Inc. with 16.5%.
Funds and institutions (13F) 90%Everyone else 10%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 38.36M | 16.55% | $321M | +4% |
| State Street Corp | 17.12M | 7.38% | $143M | +22% |
| Vanguard Capital Management LLC | 10.10M | 4.36% | $84.6M | -2% |
| Vanguard Portfolio Management LLC | 10.09M | 4.35% | $84.4M | +14% |
| Rubric Capital Management LP | 9.34M | 4.03% | $78.2M | +416% |
| Capital Research Global Investors | 8.76M | 3.78% | $73.3M | -22% |
| First Trust Advisors LP | 7.80M | 3.36% | $65.3M | +2065% |
| Geode Capital Management, LLC | 6.06M | 2.61% | $50.7M | +4% |
| Caligan Partners LP | 5.73M | 2.47% | $47.9M | +20% |
| D. E. Shaw & Co., Inc. | 5.27M | 2.28% | $44.1M | +841% |
| Nantahala Capital Management, LLC | 4.72M | 2.04% | $39.5M | – |
| Dimensional Fund Advisors LP | 3.61M | 1.56% | $30.2M | -28% |
| Goldman Sachs Group Inc | 3.51M | 1.52% | $29.4M | +25% |
| B Group, Inc. | 3.26M | 1.41% | $27.3M | +2% |
| Nuveen, LLC | 3.26M | 1.41% | $27.3M | -47% |
| Duquesne Family Office LLC | 2.78M | 1.20% | $23.3M | +80% |
| Northern Trust Corp | 2.42M | 1.04% | $20.2M | +6% |
| Morgan Stanley | 2.27M | 0.98% | $19M | -7% |
| Ranger Investment Management, L.P. | 2.12M | 0.91% | $17.7M | -7% |
| Charles Schwab Investment Management Inc | 2.09M | 0.90% | $17.5M | -0% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ADMA insiders reported $468K of open-market purchases and $3.8M of sales. 55% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 16, 2026 | Adam S Grossman | CEO | Sale plan | 15,000 | $13.72 | $206K | Form 4 |
| Nov 16, 2026 | Adam S Grossman | CEO | Sale plan | 6,000 | $13.72 | $82.3K | Form 4 |
| Nov 16, 2026 | Lawrence P. Guiheen | Director | Sale | 10,000 | $13.92 | $139K | Form 4 |
| Nov 5, 2026 | Adam S Grossman | CEO | Sale plan | 105,000 | $12.00 | $1.3M | Form 4 |
| Nov 5, 2026 | Adam S Grossman | CEO | Sale plan | 42,000 | $12.00 | $504K | Form 4 |
| May 27, 2026 | Jerrold B Grossman | Director | Purchase | 6,400 | $7.91 | $50.6K | Form 4 |
| May 12, 2026 | Jerrold B Grossman | Director | Purchase | 12,500 | $8.01 | $100K | Form 4 |
| May 11, 2026 | Jerrold B Grossman | Director | Purchase | 12,500 | $8.01 | $100K | Form 4 |
| Mar 16, 2026 | Adam S Grossman | CEO | Sale | 6,000 | $15.16 | $91K | Form 4 |
| Mar 16, 2026 | Adam S Grossman | CEO | Sale | 15,000 | $15.16 | $227K | Form 4 |
| Mar 9, 2026 | Kaitlin M. Kestenberg-Messina | Vice president | Sale | 10,096 | $15.63 | $158K | Form 4 |
| Mar 6, 2026 | Steve Elms | Director | Purchase | 7,000 | $15.39 | $108K | Form 4 |
| Mar 5, 2026 | Steve Elms | Director | Purchase | 7,000 | $15.67 | $110K | Form 4 |
| Feb 17, 2026 | Adam S Grossman | CEO | Sale | 6,000 | $16.08 | $96.5K | Form 4 |
| Feb 17, 2026 | Adam S Grossman | CEO | Sale | 15,000 | $16.08 | $241K | Form 4 |
| Dec 15, 2025 | Adam S Grossman | CEO | Sale | 6,000 | $19.79 | $119K | Form 4 |
| Dec 15, 2025 | Adam S Grossman | CEO | Sale | 15,000 | $19.79 | $297K | Form 4 |
| Nov 19, 2025 | Adam S Grossman | CEO | Sale | 6,000 | $16.00 | $96K | Form 4 |
| Nov 19, 2025 | Adam S Grossman | CEO | Sale | 15,000 | $16.00 | $240K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Adam S Grossman | President and CEO, Director | – | $3.5M | Nov 16, 2026 |
| Jerrold B Grossman | Director | $251K | – | May 27, 2026 |
| Steve Elms | Director | $217K | – | Mar 6, 2026 |
| Kaitlin M. Kestenberg-Messina | COO and SVP, Compliance | – | $158K | Mar 9, 2026 |
| Lawrence P. Guiheen | Director | – | $139K | Nov 16, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ADMA short interest
Moderate short interest. 8.1% of ADMA shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went down 10%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 18.04M ADMA shares were sold short, 8.1% of the shares outstanding, down 7.6% from the report before. At the average daily volume of 2.54M shares, buying them all back would take about 7.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 18.04M | 8.13% | -8% | 2.54M | 7.1 |
| Oct 15, 2026 | 19.53M | 8.72% | -5% | 2.98M | 6.5 |
| Sep 30, 2026 | 20.60M | 9.20% | -15% | 3.63M | 5.7 |
| Sep 15, 2026 | 24.21M | 10.81% | +1% | 2.24M | 10.8 |
| Aug 31, 2026 | 23.87M | 10.66% | +5% | 1.72M | 13.9 |
| Aug 14, 2026 | 22.68M | 10.13% | +3% | 2.84M | 8.0 |
| Jul 31, 2026 | 21.92M | 9.79% | -9% | 2.48M | 8.8 |
| Jul 15, 2026 | 24.03M | 10.37% | -1% | 2.64M | 9.1 |
| Jun 30, 2026 | 24.23M | 10.46% | +14% | 4.17M | 5.8 |
| Jun 15, 2026 | 21.28M | 9.18% | +7% | 3.28M | 6.5 |
| May 29, 2026 | 19.90M | 8.58% | -0% | 3.30M | 6.0 |
| May 15, 2026 | 19.99M | 8.63% | -3% | 8.84M | 2.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
ADMA Biologics company events
ADMA Biologics filed 9 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jun 2, 2026VoteReported shareholder vote results. Filing
- May 6, 2026ResultsReleased financial results. Filing
- May 4, 2026AnnouncementADMA Biologics, Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved the Company’s label expansion supplemental Biologics License Application for ASCENIV TM to include pediatric immune compromised patients two years of age and older. Filing
- Mar 27, 2026AnnouncementShared information with investors. Filing
- Mar 2, 2026AnnouncementOf this Current Report on Form 8-K. The press release is furnished hereto as Exhibit 99.1* and is incorporated by reference herein. Filing
- Feb 25, 2026LeadershipBrad Tade notified the Company that he is retiring from his position as Chief Financial Officer and Treasurer of the Company effective at the close of business on February 25, 2026, following the filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
ADMA Biologics financials
Famous investors that hold ADMA
8 of the 50 well-known investors we track reported holding ADMA in their latest 13F filing. The largest position is Stanley Druckenmiller's, worth $22.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Stanley Druckenmiller · Duquesne Family Office | Q3 2026 | 2.21M | $22.2M | 0.5% | -21% |
| Israel Englander · Millennium Management | Q3 2026 | 1.72M | $17.2M | 0.0% | +49% |
| Terry Smith · Fundsmith | Q3 2026 | 1.65M | $16.5M | 0.1% | No change |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 975,642 | $9.8M | 0.0% | +143% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 532,468 | $5.3M | 0.0% | -18% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 469,687 | $4.7M | 0.0% | -66% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 147,376 | $1.5M | 0.0% | New |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 98,197 | $985K | 0.0% | -76% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ADMA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Rubric Capital Management LP | 13G | 5.5% |
| Nov 16, 2026 | Rubric Capital Management LP | 13G | 5.5% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 6.1% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 6.1% |
Questions about Adma Biologics, Inc. (ADMA) stock
Who owns the most ADMA stock?
The largest reported owner of Adma Biologics, Inc. (ADMA) is BlackRock, Inc., with 16.5% of the company. In total, 321 funds and institutions reported holding ADMA at the end of Q2 2026, together about 90% of the shares. See the largest owners.
Are ADMA insiders buying or selling?
In the last 12 months, ADMA insiders reported 5 open-market purchases worth $468K and 14 sales worth $3.8M. The latest trade was on Nov 16, 2026. See every trade.
What is the short interest in ADMA?
As of Oct 30, 2026, 18.04M ADMA shares were sold short, 8.1% of the shares outstanding, down 7.6% from the report before. At the average daily volume of 2.54M shares, buying them all back would take about 7.1 trading days (days to cover). See the history.
Which famous investors hold ADMA?
8 of the 50 well-known investors we track reported ADMA in their latest 13F filing, including Stanley Druckenmiller, Israel Englander, Terry Smith. The largest position is worth $22.2M. See all holders.
Executive pay
ADMA Biologics's chief executive was paid a total of $10.2M for the year ended Dec 31, 2025, up 29% from $7.9M the year before. In the last 12 months, ADMA Biologics's executives and directors bought $468K of stock on the open market and sold $3.8M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.